Cibus CBUS
NASDAQ CBUS
$1.71 +0.01 (+0.59%)
As of: Aug 21, 2026 · 2:52 PM EDT

Cibus (CBUS) Total Non-Current Liabilities (2016 - 2026)

Cibus (CBUS) posted Total Non-Current Liabilities of $281.7 million for Q4 2025, up 1.81% sequentially from $276.7 million in Q3 2025, and up 433.48% YoY from $52.8 million in Q4 2024.

Cibus (CBUS) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Cibus has reported Total Non-Current Liabilities for 10 years, with the latest figure at $281.7 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 433.48% year-over-year to $281.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $281.7 million (up 433.48% YoY) and the FY2025 annual result came in at $281.7 million, up 433.48% from the prior year.
  • Total Non-Current Liabilities advanced to $281.7 million in Q4 2025 per CBUS's latest filing, from $276.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $281.7 million in Q4 2025 and troughed at $15.2 million in Q4 2022.
  • A 5-year average of $81.0 million and a median of $40.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities sank 32.08% in 2022, then surged 555.12% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $22.4 million in 2021, then tumbled by 32.08% to $15.2 million in 2022, then soared by 169.06% to $40.9 million in 2023, then grew by 29.2% to $52.8 million in 2024, then soared by 433.48% to $281.7 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $281.7 million, $276.7 million, and $270.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.75 Bn 130.90 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.96 Bn 77.96 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 64.98 Bn 59.80 Bn 1.37 Bn 40.00 Mn
4 Moderna 56.33 Bn 51.19 Bn 52.00 Mn 3.92 Bn
5 BeOne Medicines 42.03 Bn 36.93 Bn 1.53 Bn 1.88 Bn
6 Alnylam Pharmaceuticals 31.56 Bn 28.25 Bn 992.69 Mn 4.20 Bn
7 BioNTech SE 27.74 Bn 9.35 Bn 668.28 Mn 724.15 Mn
8 Insmed 27.47 Bn 26.31 Bn 358.27 Mn 1.17 Bn
9 Royalty Pharma 27.32 Bn 26.49 Bn - 9.32 Bn
10 Cibus 131.25 Mn 110.82 Mn - 45.13 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 45.13 Mn
Dec 31, 2025 281.66 Mn
Sep 30, 2025 276.66 Mn
Jun 30, 2025 270.21 Mn
Mar 31, 2025 259.60 Mn
Dec 31, 2024 52.80 Mn
Sep 30, 2024 55.79 Mn
Jun 30, 2024 63.98 Mn
Mar 31, 2024 39.63 Mn
Dec 31, 2023 40.87 Mn
Sep 30, 2023 46.63 Mn
Jun 30, 2023 44.11 Mn
Mar 31, 2023 17.56 Mn
Dec 31, 2022 15.19 Mn
Sep 30, 2022 17.78 Mn
Jun 30, 2022 18.19 Mn
Mar 31, 2022 23.35 Mn
Dec 31, 2021 22.36 Mn
Sep 30, 2021 22.73 Mn
Jun 30, 2021 24.84 Mn